Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Blood|June 20, 2023
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockadeMatthew Mei, Lu Chen, James Godfrey, et al.
The New England Journal of Medicine|November 1, 2018
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's LymphomaRanjana Advani, Ian Flinn, Leslie Popplewell, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 7, 2005
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host diseaseFrancisco Lopez, Pablo Parker, Auayporn Nademanee, et al.
Blood|July 9, 2005
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphomaAuayporn Nademanee, Stephen Forman, Arturo Molina, et al.
The Lancet. Haematology|November 20, 2022
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trialAlex F Herrera, Lu Chen, Yago Nieto, et al.
Blood|March 22, 2022
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICEMatthew G Mei, Hun Ju Lee, Joycelynne M Palmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2015
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in LeukemiaMichael Andreeff, Kevin R Kelly, Karen Yee, et al.
The Lancet. Haematology|November 4, 2018
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trialMichinori Ogura, Juan Manuel Sancho, Seok-Goo Cho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2013
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trialNitin Jain, Emily Curran, Neil M Iyengar, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2021
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III StudyLarry W Kwak, Juan-Manuel Sancho, Seok-Goo Cho, et al.
Pageof 7